Polypill products are pills that are in fixed-dose combinations for heart disease and high blood pressure containing a combination of several medications. These are low doses of medications like aspirin, cholesterol-lowering medications, and Medications to lower blood pressure. This combination has the potential to decrease the disease and the prevalence of cardiovascular disease. Lack of adequate medications and prescriptions is the reason high prevalence of heart disease problems. Not only for cardiovascular disease but is also used for diabetes mellitus, HIV, Tuberculosis, and other infectious diseases. polypills are more effective than usual care. shows a summary of the major clinical trials designed to assess the effect of polypill strategies for medication adherence and the prevention of CVD events. In terms of the effects of polypills on the primary and secondary prevention of CVD, Huffman et al. summarized 13 polypill trials and concluded that polypill therapy could be one of the most scalable strategies to reduce the risk of premature cardiac death, resulting in a 25% reduction in premature cardiac death by 2025 through an improvement in medication adherence and access.
World Health Federation hosted the first forum on fixed-dose combinations and included Polpill in the essential Medicine List. Those persons from low socioeconomic status have a high rate of cardiovascular disease. Polypill has the potential to mitigate the risk of cardiovascular disease, they are marketed as a fixed combination as in tablet form. Multiple clinical trials stated that polypill product has the potential to improve systolic blood pressure. As day-to-day cardiovascular diseases are increasing this market going to reach a high in coming years.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/polypill-product-market/
Global Polypill Products Market – Competitive Insight
Polypill products are used for a variety of diseases. Key players are continuously researching and developing polypill products which enhances the growth of the market. Companies’ strategic partnership, and collaboration with other companies, helps in the growth of the market.
Some of the Key Players in the Global Polypill Product Market Include –
- Pfizer, Inc.
- AstraZeneca
- Merck & Co., Inc. (Merck Sharp & Dohme Corp)
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Reddy’s Laboratories Ltd.
- Cipla, Inc.
- Cadila Pharmaceuticals
- Gebro Pharma GmbH
- Gilead Sciences, Inc.
- Takeda Pharmaceutical Company Limited
Global Polypill Product Market – Growth Drivers
The global rise in the occurrence of chronic disease will directly lead to an increase in the market in this field. Cardiovascular disease, diabetes, and obesity are rapidly increasing and to treat these multiple factors polypills are the best to use compared to other regular medications. An increase in the geriatric population means an increase in chronic disease, they always prefer to take less medicine at a time. Medication errors can be avoided as a single take is done or user-friendly, in one tablet itself combination of medications is present. As the cost of polypill is not high it is affordable by a larger number of people so it drives the market growth. For long-term medication therapies, it can used as the cost is affordable by people. Regulatory authorities are also supportive of the fixed combination doses like polypill so it will be more acceptable to people. COVID-19 made a significant impact on the market of polypill products, with more people underlying chronic conditions such as cardiovascular, diabetes, etc. People become more aware of such diseases and treatment ways to cure such diseases.
Global Polypill Product Market – Restraints
The polypill product market faces constraints due to the complex regulatory procedures. For the approval of one polypill tablet, it takes years so it is time time-consuming and complex process. Safety and efficacy issues are more as it contains multiple active ingredients which may cause drug interaction if safety is not determined properly. Strict clinical trials and post-market surveillance are required before the marketing process. Limited availability is the next restricting factor because polypills are not easily available in the market and people from rural areas are not aware of polypills. Patient knowledge and acceptance are required for getting growth in this market. The traditional way of taking medication is more accepted by people now to changing that to polypill requires extensive awareness campaigns. The price of polypill is affordable but some tablets are too costly that it not affordable by all people this limits the market of polypill. Patent expiry of products also affects the market revenue of this market. With COVID-19 19 the manufacturing, and supply chains all got disturbed and due to this, it has hurt the market of polypill products. More people focused on the treatment of COVID-19 instead of treating the chronic disease by giving polypills.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/polypill-product-market/
Global Polypill Product Market – Opportunities
The increasing global chronic disease presents a significant opportunity for the polypill product market, as age-related factors contribute to a higher prevalence of chronic diseases like heart disease, diabetes, etc. Demand for these polypill products is going to increase in emerging markets. Continuous product development is going on and advanced drug delivery systems are introduced for the effective treatment of disease. Strategic collaborations and partnerships started among companies will accelerate the development of this market. Regulatory authorities are starting awareness campaigns to make aware of people the make people know the real use of polypill tablets. Advanced and digital technologies integrated as mobile devices give personalized support to patients by using such polypill advanced technology.
Global Polypill Product Market – Geographical Insight
The market for polypill products is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East & Africa. North America is the largest market as it has a high prevalence of chronic disease and a more geriatric population. Well-established healthcare centers are another reason for the growth of the market. Continuous research and development going on contribute to the market growth. In European regions, a strong regulatory framework and support from healthcare facilitate leads to the growth of the market. Asian Pacific region has substantial growth as it has a high middle-class population and awareness of chronic disease also increasing day by day.
Global Polypill Product Market – Key Development
- On October 14, 2022, Polypill could avoid millions of premature deaths, heart attacks, and strokes.
- On January 16, 2020, AstraZeneca announced that the supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab had been accepted and granted Priority Review in the U.S. for the treatment of ovarian cancer.